Elsevier Launches Genomics Data App in Collaboration with Illumina
CAMBRIDGE, Massachusetts, May 20, 2013
CAMBRIDGE, Massachusetts, May 20, 2013 /PRNewswire/ --
Genomics Data App now available in BaseSpace Apps
Elsevier , a world-leading provider of scientific, medical and technical
products and services, announces the launch of the Genomics Data app in
collaboration with Illumina, a sequencing and array-based solutions provider
for genetics research.
The app allows researchers to share large data sets in Illumina's BaseSpace
cloud, where they can easily be reviewed and included in Elsevier's open
access journal, Genomics Data . The BaseSpace app serves as a gateway, opening
data stored in the cloud to the publishing environment for expert peer review
and wide dissemination in the form of a professional publication.
"In genomic studies we often generate large data sets of tremendous value.
Without a means to publish these data sets and get credit for them, they
easily get lost," said John Quackenbush, Co-Editor-in-Chief of Genomics Data .
"By working together with Illumina to develop a reviewing pipeline from
BaseSpace to Genomics Data , we've created a simple way for researchers to
make genomic data accessible to publication in a journal."
Through BaseSpace, authors and reviewers will also have additional access to
analytical tools, further enhancing Genomics Data ' s peer review process.
This enhanced review option can give an article attached to the data set added
credibility because reviewers are in the position to reproduce the analysis
that the authors did.
"Uploading genomic data to BaseSpace has reached critical mass. The innovative
development of the Genomics Data App demonstrates how Elsevier is able to
create new and unique opportunities for researcher collaboration," said Alex
Dickinson, Senior Vice President, Cloud Genomics at Illumina.
To view the app, please register for free on:
# # #
About Genomics Data Genomics Data is an open access journal and publishes
high quality and standardized reports summarizing results of microarray or
sequencing studies in all types of organisms. The genomic and functional
genomic data/results are intended to serve as points of record that are
enriched with data generation strategies and methods, data QC metrics, data
analysis process and algorithms, biological interpretation and conclusions.
All articles will be peer-reviewed and verified by the editorial team. For
more information please visit http://www.journals.elsevier.com/genomics-data/
Open Access Publishing at Elsevier
Elsevier has been providing open access publishing options since 2005. Today,
researchers can choose to publish in over 1,500 hybrid journals as well as
more than 39 full open access journals and these numbers will continue to grow
rapidly. All of Elsevier's open access publications have been peer reviewed,
ensuring that the broader community not only reads the latest research but
that it is factual, original and of the highest quality and ethical standards.
For more information about Elsevier's open access program, visit
Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet and Cell , and close to 20,000 book titles, including
major reference works from Mosby and Saunders. Elsevier's online solutions
include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Suite ,
which enhance the productivity of science and health professionals, and the
SciVal suite and MEDai's Pinpoint Review , which help research and health care
institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group plc , a world leading
provider of professional information solutions. The group employs more than
30,000 people, including more than 15,000 in North America. Reed Elsevier
Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed
Elsevier NV. Their shares are traded on the London, Amsterdam and New York
Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.
Media contact Bart Wacek Elsevier +1-617-397-2885 firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.